Review: Prospects for the Use of Extracts and Polysaccharides from Marine Algae to Prevent and Treat the Diseases Caused by Helicobacter pylori

Helicobacter

Volumn 20, Issue 2, 2015, Pages 89-97

  Besednova, Natalya N ^a   Zaporozhets, Tatyana S ^a   Somova, Larisa M ^a   Kuznetsova, Tatyana A ^a  

^a Institute of Epidemiology and Microbiology   (Russian Federation)

Author keywords

Fucoidan; Helicobacter pylori infection; Marine algae

Indexed keywords

ADHESIN; ALGAL EXTRACT; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ANTITOXIN; ANTIULCER AGENT; CELL RECEPTOR; CYTOTOXIN; CYTOTOXIN A; FUCOIDIN; IMMUNOMODULATING AGENT; LYPRESSIN; MARINE ALGAE EXTRACT; PHOSPHOLIPASE; POLYSACCHARIDE SULFATE; UNCLASSIFIED DRUG; UREASE; ANTIINFECTIVE AGENT; POLYSACCHARIDE;

ADAPTIVE IMMUNITY; ALGA; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIULCER ACTIVITY; BACTERIAL FLAGELLUM; BACTERICIDAL ACTIVITY; BACTERIUM ADHERENCE; BIOFILM; BIOLOGICAL ACTIVITY; DRUG TARGETING; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNOMODULATION; INFECTION PREVENTION; INFLAMMATION; INNATE IMMUNITY; MARINE ALGAE; MARINE BACTERIUM; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; SEAWEED; STOMACH MUCOSA; TARGET ORGANISM; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; MEDICAL RESEARCH; PHYTOTHERAPY; PROCEDURES; TRENDS;

ALGAE; HELICOBACTER; HELICOBACTER PYLORI;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BIOMEDICAL RESEARCH; DRUG DISCOVERY; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PHYTOTHERAPY; POLYSACCHARIDES; SEAWEED;

EID: 84924373373     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12177     Document Type: Review

References (83)

1. Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;323:1273-5.
2. Tsodikov GV, Zyakun AM, Klimova EV. Achievements and prospects of studying Helicobacter pylori infection. Epidemiol Infect Dis 2011;2:46-9.
3. Baudron CR, Franceschi F, Salles N, Gasbarrini A. Extragastric diseases and Helicobacter pylori. Helicobacter 2013;18:44-51.
4. Al-Fawaeir S, Zaid MA, Awad AA, Alabedallad B. Serum lipid profile in Helicobacter pylori infected patients. J Invest Biochem 2013;2:132-5.
5. Maev IV, Samsonov AA, Andreev NG, Kochetov SA. Clarithromycin as a core element of eradication therapy of diseases associated with Helicobacter pylori infection. Gastroenterology 2011;1:88-93.
6. Tkach SM. H. pylori infection as the main cause of gastric carcinogenesis. Health Ukraini 2009;1:32-3.
7. O'Mahony R, Al-Khtheeri H, Weerasekera D, Fernando N, Vaira D, Holton J, Basset C. Bactericidal and anti-adhesive properties of culinary and medicinal plants against Helicobacter pylori. World Gastroenterol 2005;11:7499-507.
8. Maev IV, Kucheryavyi YA, Andreev DN. Causes of inefficiency of anti-Helicobacter pylori therapy. Rus J Gastroenterol Hepatol 2013;23:62-72.
9. Loke MF, Lui SY, Ng BL, Gong M, Ho B. Antiadhesive property of microalgal polysaccharide extract on the binding of Helicobacter pylori to gastric mucin. FEMS Immun Med Microbiol 2007;50:231-8.
10. Osipenko MF, Livzan MA, Bikbulatova EA. Effectiveness of eradication therapy and patient compliance. Consilium Medicum 2013;8:14-6.
11. Skvortsov VV, Skvortsova EM. Topical issues of diagnosis and treatment of antral gastritis type B. Policlinic 2012;1:102-6.
12. Delahay RM, Rugge M. Pathogenesis of Helicobacter pylori infection. Helicobacter 2012;17:9-15.
13. Hernandes-Hernandez LDC, Lazcano-Ponce EC, Lopez-Vidal Y, Aguilar-Gutierrez GR. Relance of Helicobacter pylori virulence factors for vaccine development. Salud Publica Mex 2009;51:447-54.
14. Yevstigneev IV. Infection caused by H. pylori: state of problems and prospects. Clin Immunol Allergol Infektol 2011;6-7:14-9.
15. Buti L, Spooner E, Van der Veen AG, Rappuoli R, Covacci A, Ploegh HL. Helicobacter pylori cytotoxin-associated gene A (cagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor pathway of the host. Proc Natl Acad Sci USA 2011;108:9238-43.
16. Kusters JG, van Vliet A, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006;19:449-90.
17. Backert S, Tegtmeyer N, Selbach M. The versatility of H. pylori CagA effector protein functions: the master key hypothesis. Helicobacter 2010;15:163-76.
18. Israel DA, Peek RM. Surreptitious manipulation of the human host by Helicobacter pylori. Gut Microb 2010;1:119-27.
19. Radin JN, Gonzalez-Rivera C, Ivie SE, McClain M, Cover TL. Helicobacter pylori VacA induces programmed necrosis in gastric epithelial Cells. Infect Immun 2011;79:2535-43.
20. Winter J, Letley D, Rhead J, Atherton J, Robinson K. Helicobacter pylori membrane vesicles stimulate innate pro- and anti-inflammatory responses and induce apoptosis in Jurkatn T cells. Infect Immun 2014;82:1372-81.
21. Kalali B, Mejias-Luque R, Javaheri A, Gerhart M H. pylori virulence factors: influence on immune system. Mediators Inflamm 2014;2014:1-9.
22. Cadamuro ACT, Rossi AFT, Maniezzo NM, Silva AE. Helicobacter pylori infection: host immune response, implications on gene expression and microRNAs. World J Gastroenterol 2014;20:1424-37.
23. Cammarota G, Sanguinetti M, Gallo A, Posteraso B. Review article: biofilm formation by H. pylori as a target for eradication of resistant infection. Aliment Pharmacol Ther 2012;36:222-30.
24. Binkowska A, Biernat M, Dus E, Gosciniak G. The role of biofilm formation in pathogenesis of Helicobacter pylori infections. Prz Gastroenterol 2013;8:27-30.
25. Romanova YM, Ginzburg AL. Bacterial biofilms as a natural form of existence of bacteria in the environment and the host. J Microbiol 2011;3:99-109.
26. Coticchia JM, Sugawa C, Tran VR, Gurrola J, Kowalski E, Carron MA. Presence and density of H. pylori biofilms in human gastric mucosa in patients with peptic ulcer disease. Gastrointest Surg 2006;10:883-9.
27. Zaporozhets TS, Kuznetsova TA, Smolina TP, Besednova NN, Shevchenko NM, Zvyagintseva TN. Immunotropic and anticoagulant properties of fucoidan from the brown alga Fucus evanescens: prospects of application in medicine. J Microbiol 2006;3:54-8.
28. Kuznetsova TA, Besednova NN, Somova LM, Plekhova NG. Fucoidan extracted from Fucus evanescens prevents endotoxin-induced damage in a mouse model of endotoxemia. Marine Drugs 2014;12:886-98.
29. Cumashi A, Ushakova NA, Preobrazhenskaya ME, et al. A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic and antiadhesive activities of nine different fucoidans from brown seaweeds. Glycobiology 2007;17:541-52.
30. Matloub AA, El-Senousy WM, Hamed MA. Antiviral, antioxidant, cytotoxic and hypolipidemic activities of fucoidans isolated from Sargassum species. Planta Med 2013;79:D3.
31. Parakhonsky AP. Regulation of adhesion as a method of preventing infection. Int J Appl Basic Med Res 2009;5:126-7.
32. Ofek I, Hasty D, Sharon N. Anti-adhesion therapy of bacterial diseases: prospects and problems. FEMS Immunol Med Microbiol 2003;38:181-91.
33. Krachler AM, Orth K. Targeting the bacteria-host interface strategies in anti-adhesion therapy. Virulence 2013;4:284-94.
34. Henriksson S. Helicobacter Pylori - Multitalented Adaptation of Binding Properties. Umea, Sweden: Departament of Medical Biochemistry and Biophysics, 2012; 52.
35. Awaad AS, El-Meligy RM, Soliman GA. Natural products in treatment of ulcerative colitis and peptic ulcer. J Saudi Chem Soc 2013;17:101-24.
36. Liu H, Huang N, Yu H, Le L, Li K. Inhibition of bacterial adherence on the surface of biliare stent materials modified with chitosan. J Wuhan Univ Technol Mater Sci Ed 2010;25:795-8.
37. Smolina TP, Chernikh SV, Gorshkova RP, Nazarenko EL. Decreased of microorganisms adhesion on uroepiteliya cells using polysaccharide isolated from marine proteobacteria Pseudoalteromonas nigrifaciens. J Microbiol 2006 Application;3:58-61.
38. Yarnell END, Abascal KBS. Antiadhesion Herbs. Alternative and complementary therapies 2008;14:139-44.
39. Shibata H, Limuro M, Uchiya N, Kawamori T, Nagaoka M, Ueyama S, Hashimoto S, Yokokura T, Sugimura T, Wakabayashi K. Preventive effects of Cladosiphon fucoidan against H. pylori infection in Mongolian gerbils. Helicobacter 2003;8:59-65.
40. Masato N, Shibata H, Itsuko T, et al. Effect of fucoidan from Cladosiphon ocamuranus (Okinawa Mozuku) on the eradication of H. pylori. Cell (Tokyo) 2005;37:452-5.
41. Lutau N, Nilsson I, Wadstrom T, Ljungh A. Effect of heparin, fucoidan and other polysaccharides on adhesion of entherohepatic Helicobacter species to murine macrophages. Appl Biochem Biotechnol 2010;19:1-18.
42. De Jesus Raposo MF, de Moralis RM, de Morais AM. Health applications of bioactive compounds from marine microalgal. Life Sci 2013;93:479-86.
43. Raposo MFJ, Morais RMC, Morais AMMB. Bioactivity and applications of sulfated polysaccharides from marine microalgae. Marine Drugs 2013;11:233-52.
44. Hashimoto S, Haruji N, Yokokura H. Antiulcer agent and adhesion inhibitor for H. pylori. Patent. EP 0645143B1, 31.05.2000.
45. Sinurat E, Marraskurante E. Fucoidan from brown seaweed and its bioactivity. Squalen 2012;7:131-8.
46. Radhavendran HRB, Srinivasan P, Rekha S. Immunomodulatory activity of fucoidan against aspirin-induced gastric mucosal damage in rats. Int Immunopharmacol 2011;11:157-63.
47. Amornlerdpison D, Peerapompisal Y, Taesoticul T, Noiraraksar T, Kanjanapothi D. Gastroprotective activity of Padina minor Yamada. Chiang Mai J Sci 2009;36:92-103.
48. Amornlerdpison D, Peerapompisal Y, Rujjanawate C, Taesoticul T, Nualchareon M, Kanjanapothi D. Hypotensive activity of some marine algae. J Sci Res Chula 2007;section T:363-8.
49. Amornlerdpison D, Peerapompisal Y, Rujjan awate C, Taesoticul T, Nualchareon M, Kanjanapothi D. Antioxidant activity of Padina minor Yamada. KMITh Sci Technol 2007b;7:1-7.
50. Amaro HM, Barros R, Guedes AC, Souzo-Pinto I, Malcata FX. Microalgal compounds modulate carcinogenesis in the gastrointestinal tract. Trends Biotechnol 2013;31:92-8.
51. Krylov V, Ustyuzhanina NE, Grachev AA, Nifantiev NE. Synthesis of large fucoidan fragments- potential inhibitors of microbial adhesion. 4th Baltic meeting on Microbial Carbohydrates. Chiitely, Finland. 19-22 September, 2010: (Meeting Abstract). 50.
52. Back HI, Kim SY, Park SH, et al. Effect of fucoidan supplementation on Helicobacter pylori in humans. FASEB J 2010;24: (Meeting Abstract Supplement) Ib 347.
53. Rendueles O, Kaplan JB, Ghigo JM. Antibiofilm polysaccharides. Environ Microbiol 2013;15:334-46.
54. Daoud L, Sura M, Abdel-Massih RM. Pectin shows antibacterial activity against Helicobacter pylori. Adv Biosci Biotechnol 2013;4:273-7.
55. Nagaoka M, Shibata H, Takagi I, Shusuke H. Antibacterial agents and process for producing the same. Patent 7498317, 3 March 2009.
56. Fehlings M, Drobbe I, Moos V, et al. Comparative analysis of the interaction of H. pylori with human dendritic cells, macrophages, and monocyhtes. Infect Immun 2012;80:2724-34.
57. Chatter R, Ben Othman R, Rabhi S, Kladi M, Tarhouni S, Vagias C, Roussis V, Guizani-Tabbane L, Kharrat R. In vivo and in vitro anti-inflammatory activity of neorogioltriol, a new diterpene extracted from the red algae Laurencia glandulifera. Marine Drugs 2011;9:1293-306.
58. D'Orazio N, Gammone MA, Gemello E, Girolamo M, Cusenza S, Riccioni G. Marine bioactives: pharmacological properties and potential applications against inflammatory diseases. Marine Drugs 2012;10:812-33.
59. Chaves LS, Nicolau LA, Silva RO, Barros FC, Freitas AL, Aragao KS, Ribeiro RA, Souza MH, Barbosa AL, Medeiros JV. Antiinflammatory and antinociceptive effects in mice of a sulfated polysaccharide fraction extracted from the marine red algae Gracillaria caudate. Immunopharmacol Immunotoxicol 2013;35:93-100.
60. Renju GL, Muraleedhara Kurup G, Saritha Kumari CH. Anti-inflammatory activity of lycopene isolated from Chlorella marina on Type II collagen induced arthritis in Sprague Dawley rats. Immunopharmacol Immunotoxicol 2013;35:282-91.
61. Dore CM, Faustino Alves MG, Will LS, Costa TG, Sabry DA, de Souza RLA, Accardo CM, Rocha HA, Filgueira LG, Leite EL. A sulfated polysaccharide, fucans, isolated from brown algae Sargassum vulgare with anticoagulant, antithrombotic, antioxidant and anti-inflammatory effects. Carbohydr Polym 2013;91:467-75.
62. Bachelet-Violette L, Bertholoni D, Lavigne R, Vassy R, Jandrot-Perrus M, Chaubet F, Letourneur D. Affinity of low molecular weight fucoidan for P-selectin triggers its binding to activated human platelets. Arch Cardiovasc Dis 2009;102:36.
63. Galebskaya LV, Rumina EV, Bogomaz TA, Preobrazhenskya MV. Mechanisms of fucoidan action on human complement. Biomed Chem 2003;6:542-7.
64. Senni K, Gueniche F, Foucault-Bertaud A, et al. Fucoidan, a sulfated polysaccharide from brown algae is a potent modulator of connective tissue proteolisis. Arch Biochem Biophys 2006;445:56-64.
65. Park HY, Min HH, Cheol R, Cheng-Yun J, Gi-Yong K, Il-Whan C, Nam D, Taek-Jeong N, Taeg KK, Yung HS. Anti-inflammatory effect of fucoidan through inhibition of NF-kB, MAPK and Act activation in lipopolysaccharide-induced BV2 microglia cells. Food Chem Toxicol 2011;49:1745-52.
66. Jeong DH, Kim KBWR, Kang BK, Jung SA, Kim HJ, Jeong HY, Bark SW, Ahn DH. Anti-inflammatory activity of the Undaria pinnatifida water extract. J Appl Biol Chem 2012;55:221-5.
67. Yoon WJ, Ham YM, Kim KN, Park SY, Lee NH, Hyun CG, Lee NJ. Anti-inflammatory activity of brown alga Dictiota dichotoma in murine macrophage RAW264.7 cells. J Med Plant Res 2009;3:1-8.
68. Matsumoto S, Nagaoka M, Hara T, Mistuyama K, Ueyama S, Kimura-Tagaki I. Fucoidan derived from Cladosiphon ocamuranus Tokida ameliorates murine chronic colitis through the down-regulation of interleukin-6 production on colonic epithelial cells. Clin Exp Immunol 2004;136:432.
69. Kang CH, Choi YH, Choi W, Lee J, Kim G. Inhibition of lipopolysaccharide-induced iNOS, COX-2 and TNFα expression by aqueous extract of Orixa japonica in RAW 264.7 cells via suppression of NF-kB activity. Trop J Pharm Res 2011;10:161-8.
70. Do H, Pyo S, Sohn EH. Supression of iNOS expression by fucoidan is mediated by regulation of p38 MAPK, JAK/STAT, AP-1 and IRF-1 and depends on up-regulation of scavenger receptor B1 expression in TNFα and IFNγ-stimulated C6 glioma cells. J Nutr Biochem 2010;21:671-8.
71. Jayasooriya RGPT, Kang CH, Jang YJ, Kang SH, Dilshara MG, Choi YH, Moon DO. Methanol extract of Myelophycus caespitosus inhibits the inflammatory response in LPS-stimulated BV2 microglial cells by downregulating NF-kB via inhibition of the Act signaling pathway. Trop J Pharm Res 2012;11:917-24.
72. Huang XW, Luo RH, Zhao Q, Shen LZ, Huang LL, An XY, Zhao LG, Wang J, Huang YZ. Helicobacter pylori induces mitochondrial DNA mutation and reactive oxygen species level in AGS cells. Int J Med Sci 2011;8:56-67.
73. Bagchi DE, McGinn TR, Ye X, Bagchi M, Krohn RL, Chatterjee A, Stohs SJ. Helicobacter pylori-induced oxidative stress and DNA damage in a primary culture of human gastric mucosal cells. Dig Dis Sci 2002;47:1405-12.
74. Pattanayak SP, Priyashree S. Hepatoprotective activity of the leaf extracts from Dendrophthoe falcate Ettingsh against carbon tetrachloride-induced toxicity in wistar albino rates. Pharmacogn Mag 2008;4:218-22.
75. 4 induced oxidative damage in Wistar rats. Asian Pac J Trop Med 2010;3:696-701.
76. Vadlapudi V, Kaladhar D, John paul M, Suresh kumar S, Behara M. Antioxidant activities of marine algae: a review. Int J Rec Sci Res 2012;3:574-80.
77. Li F, Wei X, Zhao XR. Fucoidan: structure and bioactivity. Molecules 2008;13:1671-95.
78. Makarenkova ID, Akhmatova NK, Semenova IB, Besednova NN, Zvyagintseva TN. Sulfated polysaccharides from brown seaweed - inducers of dendritic cell maturation. Pacific Med J 2009;3:36-9.
79. Ihan A, Pinchuk IV, Beswick EJ. Inflammation, immunity, and vaccines for Helicobacter pylori infection. Helicobacter 2012;17:16-21.
80. Adamsson J, Lundin SB, Hansson LE, Sjovall H, Svennerholm AM. Immune responses against Helicobacter pylori in gastric cancer patients and in risk groups for gastric cancer. Helicobacter 2013;18:73-82.
81. Makarenkova ID, Logunov DYu, Tukhvatulin AI, Semenova IB, Zvyagintseva TN, Gorbach VI, Ermakova SP, Besednova NN. Sulfated polysaccharides of brown seaweeds are ligands of Toll-like receptors. Biomed Chem 2012;6:75-80.
82. Dugina VV, Kuzin VB, Lebedeva NV, et al. Effect of immunomodulate therapy on lysozyme activity and severity of contamination of Helicobacter pylori in chronic gastric ulcer and duodenal ulcer. Modern Med Technol 2011;1:138-40.
83. Konorev MR. Application of immunomodulator N-acetylglucosamine-N-atsetilmuramildipeptid during the three-component anti Helicobacter therapy. Therapeutic Archive 2012;12:66-70.